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Objectives The purpose of this study was to investigate the 2-year outcome of percutaneous coronary intervention (PCI)
guided by fractional flow reserve (FFR) in patients with multivessel coronary artery disease (CAD).
Background In patients with multivessel CAD undergoing PCI, coronary angiography is the standard method for guiding stent
placement. The FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study showed
that routine FFR in addition to angiography improves outcomes of PCI at 1 year. It is unknown if these favorable
results are maintained at 2 years of follow-up.
Methods At 20 U.S. and European medical centers, 1,005 patients with multivessel CAD were randomly assigned to PCI
with drug-eluting stents guided by angiography alone or guided by FFR measurements. Before randomization,
lesions requiring PCI were identified based on their angiographic appearance. Patients randomized to
angiography-guided PCI underwent stenting of all indicated lesions, whereas those randomized to FFR-guided
PCI underwent stenting of indicated lesions only if the FFR was 0.80.
Results The number of indicated lesions was 2.7  0.9 in the angiography-guided group and 2.8  1.0 in the FFR-
guided group (p  0.34). The number of stents used was 2.7  1.2 and 1.9  1.3, respectively (p  0.001). The
2-year rates of mortality or myocardial infarction were 12.9% in the angiography-guided group and 8.4% in the
FFR-guided group (p  0.02). Rates of PCI or coronary artery bypass surgery were 12.7% and 10.6%, respec-
tively (p  0.30). Combined rates of death, nonfatal myocardial infarction, and revascularization were 22.4%
and 17.9%, respectively (p  0.08). For lesions deferred on the basis of FFR 0.80, the rate of myocardial in-
farction was 0.2 % and the rate of revascularization was 3.2 % after 2 years.
Conclusions Routine measurement of FFR in patients with multivessel CAD undergoing PCI with drug-eluting stents signifi-
cantly reduces mortality and myocardial infarction at 2 years when compared with standard angiography-guided
PCI. (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation [FAME]; NCT00267774) (J Am
Coll Cardiol 2010;56:177–84) © 2010 by the American College of Cardiology Foundation
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2-Year Results of the FAME Study July 13, 2010:177–84With the introduction of drug-
eluting stents (DES), the per-
centage of patients with mul-
tivessel coronary artery disease
(CAD) in whom percutaneous
coronary intervention (PCI) is
performed, has increased (1). Be-
cause DES are expensive and are
associated with potential late
complications, their appropriate
use is critical (2). However, in
patients with multivessel CAD,
identifying which lesions cause
ischemia and warrant stenting
can be difficult. Although coro-
nary angiography often underes-
imates or overestimates a lesion’s functional severity, it is
till the standard technique for guiding PCI in patients with
ultivessel coronary artery disease (3).
Fractional flow reserve (FFR) is an index of the physio-
ogic significance of a coronary stenosis and is defined as
aximal blood flow in a stenotic artery as a ratio to normal
aximal flow (4). It can be easily measured during coronary
ngiography by the ratio of distal coronary pressure mea-
ured with a coronary pressure guidewire to aortic pressure
easured simultaneously with the guiding catheter during
aximum hyperemia. An FFR value of 0.80 discriminates
oronary stenoses responsible for ischemia with an accuracy
90% (4,5). Retrospective studies suggest that in patients
ith multivessel CAD, FFR-guided PCI is associated with
favorable outcome with respect to event-free survival (6).
For patients with multivessel coronary artery disease,
dentifying an approach to PCI that would result in a more
udicious use of stents, while still achieving complete relief
f myocardial ischemia, could improve clinical outcome and
ecrease health care costs. The objective of the FAME
Fractional Flow Reserve Versus Angiography for Multives-
el Evaluation) study was to compare treatment based on
easurement of FFR in addition to angiography to the
urrent practice of treatment solely guided by angiography
n patients with multivessel CAD amenable for PCI. The
AME study showed that after a follow-up of 1 year, the
ate of major adverse cardiac events (MACE) was reduced
ignificantly by approximately 30%, and similar high per-
entages of patients were free from angina (7). The purpose
f this paper was to investigate whether the favorable
utcome of FFR-guided PCI in the FAME study is
aintained at 2 years.
ethods
tudy design. The design of this study has been described
reviously (8). In eligible patients with multivessel CAD,
he investigator indicated which lesions had stenosis of at
east 50% and were thought to require PCI on the basis of
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CK-MB  creatine kinase-
myocardial band
DES  drug-eluting stent(s)
FFR  fractional flow reserve
MACE  major adverse
cardiac event(s)
PCI  percutaneous
coronary interventionngiographic appearance and clinical data. Patients werehen randomly assigned to either angiography-guided PCI
r FFR-guided PCI. (Fig. 1). Patients assigned to angio-
raphic guidance underwent stenting of all indicated lesions
ith DES. In patients assigned to FFR guidance, first FFR
as measured in each diseased coronary artery and DES
ere placed in indicated lesions only if the FFR was 0.80 or
ess. The study protocol was approved by the internal review
oard of each participating center. An independent clinical
vent committee blinded to treatment assignment adjudi-
ated all events. Data management and statistical analysis
ere performed by an independent data coordinating cen-
er. The study sponsors had no role in the methods, data
cquisition, data analysis, reporting, or publication of this
tudy.
tudy population. Patients were included in the study if
hey had multivessel CAD, defined as coronary artery
tenoses 50% diameter stenosis in at least 2 of the 3 major
picardial coronary arteries, which were thought to require
CI. Patients with ST-segment elevation myocardial in-
arction could be included if the infarction had occurred at
east 5 days before PCI. Enrollment and PCI of patients
Angiography-guided PCI
PCI with DES performed on all
indicated lesions
FFR-guided PCI
PCI with DES performed on
indicated lesions only if FFR 0.80
Randomization
1005 patients with
multivessel coronary artery disease
referred for PCI
1 year
Primary Endpoint: composite of death, myocardial and
revascularization
2 years
Key Secondary Endpoints: individual rates of death,
myocardial infarction, revascularization, MACE, and functional
status
Identification of all lesions with stenosis 50%
for which stenting is planned
Figure 1 The FAME Study Flowchart
Flowchart of the FAME (Fractional Flow Reserve Versus Angiography for Mul-
tivessel Evaluation) study. In all, 1,005 patients with multivessel coronary
artery disease were randomly assigned to angiography-guided percutaneous
coronary intervention (PCI) (n  496) or fractional flow reserve (FFR)-guided PCI
(n  509). The key secondary end points at 2 years were individual rates of
death, myocardial infarction, revascularization, major adverse cardiac events
(MACE), and functional status. DES  drug-eluting stent(s).
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July 13, 2010:177–84 2-Year Results of the FAME Studyith non–ST-segment elevation myocardial infarction
ould occur earlier than 5 days if the peak creatinine kinase
as 1,000 IU. Patients who had undergone previous PCI
ould be included in the study. Patients with angiographi-
ally significant left main coronary artery disease, previous
oronary artery bypass surgery, cardiogenic shock, extremely
ortuous or calcified coronary arteries, a life expectancy of
2 years, pregnancy, or a contraindication to DES place-
ent were excluded.
reatment. The PCI was performed using standard tech-
iques. The FFR was measured with a coronary pressure
uidewire (Radi, St. Jude Medical, Uppsala, Sweden) at
aximal hyperemia induced by intravenous adenosine, ad-
inistered at 140 g/kg/min through a central vein. Hy-
eremic pressure pull-back recordings were performed as
escribed previously (8,9). All included patients were
reated with aspirin and clopidogrel for at least 1 year.
uantitative coronary angiography was performed off line
nd is extensively described elsewhere (10,11).
nd points and 2-year follow-up. MACE were defined as
composite of death, myocardial infarction, or any repeat
evascularization. The primary end point was the rate of
ACE by 1 year. Secondary end points included death and
yocardial infarction rates and MACE and its individual
omponents at 2 years, procedure time, amount of contrast
gent used, functional class at 1 and 2 years, and number of
ntianginal medications. Cost effectiveness was a secondary
nd point as well. Death was defined as all-cause mortality.
yocardial infarction was defined as a threefold or greater
levation of creatine kinase-myocardial band (CK-MB)
evel or new Q-waves in 2 contiguous leads of the
lectrocardiogram (ECG) (12). Total CK and CK-MB
evels were measured in all patients between 12 and 24 h
fter PCI. After discharge, follow-up was performed at 1
onth, 6 months, 1 year, and 2 years (13).
tatistical analysis. All enrolled patients were included in
he analysis of primary and secondary end points according
o the intention-to-treat principle. Categorical variables
ncluding the primary end point, and its components are
escribed as proportions and were compared by chi-square
est. Continuous variables are described as mean and stan-
ard deviation and were compared by unpaired t test or
ann-Whitney U test. A 2-sided p value of 0.05 was
onsidered to indicate statistical significance. Kaplan-Meier
urves are presented to describe the time-to-event distribu-
ions for the different end points. All statistical analyses
ere performed with SAS software version 9.1 (SAS Insti-
ute, Cary, North Carolina).
esults
aseline characteristics and angiographic data. Between
anuary 2006 and September 2007, 1,005 patients were in-
luded in 20 centers in the U.S. and Europe. Of these, 496
ere randomly assigned to angiography-guided PCI and 509o FFR-guided PCI. Baseline characteristics of the 2 groups oere similar, as were the number of indicated lesions and
ngiographic extent and severity of CAD (Table 1).
rocedural results. In all, 2,415 stents were placed, of
hich 2,339 (96.9%) were DES. Significantly more stents
er patient were placed in the angiography-guided group
ompared with the FFR-guided group (2.7  1.2 vs. 1.9 
.3; p  0.001) (Table 2). In the FFR-guided group, FFR
as successfully measured in 94% of all lesions. In 874
63%) lesions, FFR was 0.80 or less, and these lesions were
tented as per protocol. In 513 (37%) lesions, FFR was
0.80, and these lesions were not stented. The procedure
ime was similar in the 2 groups (70  44 min in the
ngiography-guided group and 71  43 min in the FFR-
uided group; p  0.51). Significantly more contrast agent
as used in the angiography-guided group than in the
FR-guided group (302  127 ml vs. 272  133 ml; p 
.001). Length of hospital stay was 3.7  3.5 days in the
ngiography-guided group versus 3.4  3.3 days in the
FR-guided group (p  0.05).
dverse events and freedom from angina at 2 years.
omplete 2-year follow-up was obtained in 93.6% of
atients (36 were lost to follow-up in the angiography-
uided group, and 29 were lost to follow-up in the FFR-
uided group [p 0.31]). All-cause mortality at 2 years was
.8% (n  19) in the angiography-guided group and 2.6%
n  13) in the FFR-guided group (p  0.25) (Table 3).
yocardial infarction occurred in 9.9% (n  49) in the
ngiography-guided group and 6.1% (n  31) in the
FR-guided group (p  0.03). Of these patients, 13 (2.6%)
ulfilled the Academic Research Consortium definition of
efinite or probable stent thrombosis in the angiography-
uided group versus 8 patients (1.6%) in the FFR-guided
roup.
The 2-year rate of death or myocardial infarction, which
as not a pre-specified secondary end point but is an
mportant clinical variable, was 12.9% (n  64) in the
ngiography-guided group and 8.4% (n  43) in the
FR-guided group (p  0.02). Revascularization rate was
2.7% (n 63) in the angiography-guided group and 10.6%
n 54) in the FFR-guided group (p 0.30). After 2 years,
ACE had occurred in 111 patients (22.4%) in the
ngiography-guided group and in 91 patients (17.9%) in the
FR group (p  0.08). Event-free survival is shown by
aplan-Meier curves (Fig. 2). At 2 years, 76% of the
atients were free from angina in the angiography-guided
roup compared with 80% in the FFR-guided group (p 
.14) (Fig. 3).
utcome of the deferred lesions in the FFR-guided
roup. In the 509 patients in the FFR-guided group,
,329 stenoses were successfully measured by FFR, of
hich 816 were stented (FFR 0.80) and 513 were
eferred (FFR 0.80). During the follow-up of 2 years,
mong these 509 patients, 9 (1.8%) myocardial infarctions
ccurred after the index hospitalization of which 8 (1.6%)
ere related to a new lesion or were stent related, whereas
nly 1 (0.2%) myocardial infarction occurred in an originally
d
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2-Year Results of the FAME Study July 13, 2010:177–84eferred lesion (Fig. 4). In 53 (10.4%) patients in the
FR-guided group, 1 or more repeat revascularizations were
erformed, of which 37 (7.2%) were related to a new or
estenotic lesion and only 16 (3.2%) to an originally deferred
esion.
iscussion
he FAME study showed that in patients with multivessel
AD, favorable outcome after routine measurement of FFR
uring PCI as compared with the standard strategy of PCI
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
Angiog
(n
Demography
Age, yrs 64.
Sex
Male 3
Female 1
Clinical
Angina (CCS class)
I 1
II 1
III 1
IV
History
Previous myocardial infarction 1
Previous PCI 1
Diabetes mellitus 1
Hypertension 3
Current smoker 1
Hypercholesterolemia 3
Positive family history 1
Unstable angina
With dynamic ECG changes
Without dynamic ECG changes
Left ventricular ejection fraction, % 5
Medication
Beta-blocker 3
Calcium antagonist
Nitrates 1
ACE inhibitor/ARB 2
Statin 3
Aspirin 4
Clopidogrel 2
Angiography
Indicated lesions per patient† 2.
50%–70% narrowing 5
70%–90% narrowing 5
90%–99% narrowing 2
Total occlusion
Lesions segments 1, 2, 3, 6, 7, 11 9
Patients with proximal LAD lesion 1
Patients with total occlusion
Values are mean  SD or n (%). *All categorical variables were c
Mann-Whitney U test, except age, which was normally distributed an
lesions to be included in the study and classified them according to s
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor
FFR  fractional flow reserve; LAD  left anterior descending artery;uided by angiography alone is maintained at 2-year follow- tp. The combined rate of death and myocardial infarction as
ell as rate of myocardial infarction alone were significantly
ower among patients in the FFR-guided group. Although
he composite end point of death, myocardial infarction, or
he need for revascularization was no longer significantly
ower in the FFR-guided group, the absolute difference in
vent rates was similar to what was demonstrated at 1 year.
he high percentage of patients free from angina was
aintained at 2 years, and the FFR-guided strategy resulted
n a similar, if not improved, functional status. Moreover,
Group
)
FFR Group
(n  509) p Value*
.2 64.6 10.3 0.47
0.30
) 384 (75)
) 125 (25)
0.13
) 132 (26)
) 170 (33)
) 132 (26)
) 75 (15)
) 187 (37) 0.84
) 146 (29) 0.34
) 123 (24) 0.65
) 312 (61) 0.10
) 138 (27) 0.12
) 366 (72) 0.62
) 205 (41) 0.49
) 73 (14) 0.09
) 77 (15) 0.29
57 11 0.92
) 395 (78) 0.55
) 121 (24) 0.09
) 167 (33) 0.27
) 267 (52) 0.74
) 417 (82) 0.45
) 465 (91) 0.92
) 310 (61) 0.51
9 2.8 1.0 0.34
) 624 (44)
) 530 (37)
) 202 (14)
58 (4)
) 1,032 (73) 0.27
) 210 (41) 0.22
) 54 (10.6) 0.08
ed by chi-square test; all continuous variables were compared by
ared by t test. †Before randomization, the investigator indicated all
by visual estimation, based on the angiogram.
r; CCS  Canadian Cardiovascular Society; ECG  electrocardiogram;
ercutaneous coronary intervention.raphy
 496
2 10
60 (73
36 (27
15 (23
65 (33
18 (24
98 (20
80 (36
29 (26
25 (25
27 (66
56 (32
62 (74
90 (39
91 (18
87 (18
7 12
77 (76
96 (19
79 (36
55 (51
97 (80
54 (92
92 (59
7 0.
50 (41
53 (41
07 (15
40 (3)
60 (71
86 (38
37 (7.5
ompar
d comp
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July 13, 2010:177–84 2-Year Results of the FAME Study0.80 was excellent, underscoring the safety of the FFR-
uided approach.
In our study, the incidence of all types of adverse events
as consistently reduced by roughly 30%. The absolute risk
or MACE was reduced by 4.5%, which means that using
FR for 22 patients can prevent 1 adverse event. Routine
easurement of FFR probably improved outcomes by
llowing more judicious use of stents and equal relief of
Procedural ResultsTable 2 Procedural Results
Procedure time, min†
Contrast agent used, ml
Drug-eluting stents
Drug-eluting stents used per patient
Total stent length, mm
Average stent diameter per patient, mm
Lesions successfully stented‡
Total drug-eluting stents used
FFR results
Lesions successfully measured by FFR§
FFR, all lesions
FFR 0.80, ischemic lesions
FFR 0.80, nonischemic lesions
Lesions with FFR 0.80
Lesions with FFR 0.80
Procedural and 1-yr costs
Materials, U.S.$
Hospital stay at baseline admission, days
Incremental health care costs at 1 year, U.S.$¶
Values are mean  SD, n (%), or n. *All categorical variables wer
“drug-eluting stents used per patient” were compared by Mann-Whit
catheter until removal of last guiding catheter. ‡Percentage of the lesi
FFR0.80 (FFR group). §Percentage of the number of all indicated lesi
occluded arteries to which a default FFR value of 0.50 was assigned, w
reasons. The materials used during the index procedure (PCI) were rec
translated into U.S. dollars. ¶Incremental health care costs is the su
hospitalization days for the index procedure, the costs for hospitalizat
coronary artery bypass graft surgery or repeat PCI in the first year, if a
N/A  not available; other abbreviations as in Table 1.
nd Points at 2 YearsTable 3 End Points at 2 Years
Angiography Group
(n  496)
Events at 2 yrs
Total number of events 142
Number of events per patient 0.29 0.60
Death 19 (3.8)
Myocardial infarction 49 (9.9)
CABG or repeat PCI 63 (12.7)
Death or myocardial infarction 64 (12.9)
Death, myocardial infarction, CABG, or repeat PCI 111 (22.4)
Functional status at 2 yrs
Patients without event and free from angina† 284 (64.8)
Patients free from angina† 332 (75.8)
Number of antianginal medications‡ 1.2 0.8
alues are n, mean  SD, or n (%). *All categorical variables were compared by chi-square test; al
test. †Patients with missing information on angina status were excluded from the analysis. ‡Antiangin
CABG  coronary artery bypass graft surgery; CI  confidence interval; RRR  relative risk reduction;schemia. Performing PCI of all angiographic stenoses,
egardless of their ischemic potential, diminishes the benefit
f relieving ischemia by exposing the patient to additional
tent-related risk, whereas PCI of ischemic stenoses only
FFR 0.80) is beneficial because the risk of stent throm-
osis or restenosis is outweighed by the significant reduction
n the risk of ischemic events without stent placement.
hus, by systematically measuring FFR, the benefit of PCI
graphy Group
 496)
FFR Group
(n  509) p Value*
0 44 71 43 0.51
2 1 272 133 0.001
.7 1.2 1.9 1.3 0.001
.9 24.6 37.9 27.8 0.001
6 0.33 2.92 0.36 0.13
,237 (92) 819 (94) 0.07
1,359 980 0.001
N/A 1,329 (94)
N/A 0.71 0.18
N/A 0.60 0.14
N/A 0.88 0.05
N/A 874 (63)
N/A 513 (37)
07 2,819 5,332 3,261 0.001
.7 3.5 3.4 3.3 0.05
14,357 12,291 0.001
ared by chi-square test; all continuous variables and the variable
est. †Procedure time was defined as time from introduction of first
icated at baseline (angiography group), percentage of the lesions with
those 85 lesions without FFRmeasurement, 58 (4.1%) were the totally
in 27 (1.9%) lesions, FFR could not be measured because of technical
nd their costs were calculated according to the actual local price and
e costs of materials used during the index procedure, the costs of
s for major adverse cardiac events in the first year, and the costs for
le.
FFR Group
(n  509) p Value*
RR With FFR Guidance
(95% CI)
106
0.21 0.48 0.17
13 (2.6) 0.25 0.67 (0.33–1.34)
31 (6.1) 0.03 0.62 (0.40–0.95)
54 (10.6) 0.30 0.84 (0.59–1.18)
43 (8.4) 0.02 0.65 (0.45–0.94)
91 (17.9) 0.08 0.80 (0.62–1.02)
315 (68.2) 0.29
369 (79.9) 0.14
1.2 0.7 0.68
uous variables and the variable “number of events per patient” were compared by Mann-WhitneyAngio
(n
7
30
2
51
2.9
1
6,0
3
e comp
ney U t
ons ind
ons; of
hereas
orded a
m of th
ion dayl contin
al medications included beta-blockers, calcium antagonists, nitrates.
other abbreviations as in Table 1.
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2-Year Results of the FAME Study July 13, 2010:177–84an be maximized by accurately discriminating the lesions
or which revascularization will provide the most benefit.
trengths and limitations of the FAME study. The
AME study has several specific strengths that should be
entioned. First, because of the liberal inclusion and few
xclusion criteria, the study truly reflects everyday practice in
erforming PCI for multivessel disease. This position is
urther corroborated by the fact that 53% of all screened
atients were actually included in the study (7) and that 43
atients were included per center per year, both numbers
xceptionally high for this kind of study (14,15).
Second, the majority of the stenoses was located in the
roximal or mid-segments of the 3 major coronary arteries,
nd in almost 40% of the patients, a proximal left anterior
escending artery stenosis was 1 of the target lesions.
urthermore, patients who had undergone PCI in the past
ere not excluded, as is mostly the case in other studies
omparing outcome after different treatment modalities in
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Figure 2 Kaplan-Meier Survival Curves
Kaplan-Meier survival curves according to study group for survival free from (A) ma
and (D) revascularization. The red curve indicates the angiography-guided percuta
reserve (FFR)-guided PCI group. CABG  coronary artery bypass graft surgery.0.70
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Figure 3 Patient Follow-Up
Percentage of patients treated by angiography-guided strategy (red bars) and
fractional flow reserve (FFR)-guided strategy (blue bars) who were completely
free from angina at baseline, and at 1- and 2-year follow-up.
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July 13, 2010:177–84 2-Year Results of the FAME StudyThird, the reduction of event rate by 30% was consis-
ently present for all types of events. Fourthly, the high
ercentage of patients free from angina after 2 years under-
ines that PCI—especially when applied appropriately—is a
ery effective way to eliminate ischemia and improve quality
f life. Lastly, the very low late infarction and late revascu-
arization rate of initially deferred lesions underscores the
afety of an FFR-guided approach to PCI for multivessel
isease.
Our results also suggest that outcomes of PCI as com-
ared with those achieved by medical treatment, such as in
he COURAGE (Clinical Outcomes Utilizing Revascular-
zation and Aggressive Drug Evaluation) trial (12,14) or
y coronary artery bypass graft surgery, such as in the
YNTAX (Synergy Between PCI With Taxus and Cardiac
urgery) trial (15), might be improved if the PCI is
erformed with FFR guidance, ensuring a functionally
omplete revascularization with more appropriate use of
tents (10). A substudy of the COURAGE trial (18), which
emonstrated lower rates of death or myocardial infarction
n those patients with the greatest relief of ischemia, further
upports the concept that PCI should be guided by physi-
logic considerations and not solely by anatomic ones.
It has been suggested that including stenoses of 50% to
0% in the FAME study might have biased the outcome
ecause many interventionalists would not stent such le-
Figure 4 2-Year Outcome of Stenoses in FFR Group
Initially Deferred on Basis of FFR >0.80
Numbers of late myocardial infarction and repeat revascularization of the ste-
noses in the fractional flow reserve (FFR) group initially deferred from stenting
on the basis of FFR 0.80, and in stenoses in the FFR group that were
stented because of FFR 0.80.ions. However, just for these lesions (1,174 of a total of,764 stenoses), the correlation between anatomic and phys-
ologic severity was worse. Not stenting such stenoses on the
asis of the angiogram would have left untreated a hemody-
amically significant stenosis in 35% of all lesions (11).
It can be questioned whether the difference in events is
ue to the first 48 h with catch-up of events thereafter.
owever, that was not the case. The number of small,
eriprocedural infarctions (CK-MB 3 to 5 times the upper
imit of normal) was low: 3.2% and 2.4%, respectively; and
bsolute differences in MACE were 2.2% at hospital dis-
harge, 5.1% at 1 year, and 4.5% at 2 years, whereas the
ifference in rate of myocardial infarction even further
ncreased at the advantage of the FFR-guided group during
he second year of follow-up.
Another potential limitation could be that FFR measure-
ent requires some extra manipulations, preferably a central
enous line if intravenous adenosine is used, and some basic
nowledge about interpretation. But given a well-designed
nfrastructure in the catheterization laboratory and an expe-
ienced interventionalist, it is a simple and quick procedure
o be performed without significant delay, as shown in this
tudy.
Finally, the current data are restricted to a 2-year follow-
p. Theoretically, unstented lesions in the FFR-guided
roup could progress and lead to future events beyond this
ime horizon. We intend to collect data up to a follow-up of
years for the present study.
onclusions
n patients with multivessel CAD undergoing PCI with
ES, routine measurement of FFR as compared with PCI
uided by angiography alone results in a significant reduc-
ion of the rate of mortality and myocardial infarction at 2
ears, and supports the evolving paradigm of revasculariza-
ion of ischemic lesions and medical treatment of nonisch-
mic ones.
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